<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833480</url>
  </required_header>
  <id_info>
    <org_study_id>H14-02277</org_study_id>
    <nct_id>NCT02833480</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota</brief_title>
  <acronym>DISARM</acronym>
  <official_title>A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of budesonide (using Symbicort which is budesonide and&#xD;
      formoterol) and fluticasone (using Advair which is fluticasone and salmeterol) on the airway&#xD;
      microorganisms of patients with moderate-to-severe chronic obstructive pulmonary disease&#xD;
      (COPD). This is a randomized, parallel group, two-centered clinical trial study to evaluate&#xD;
      the effects of a 12 week treatment with Symbicort 400 mcg BID and Advair 250 mcg BID (via&#xD;
      Diskus) on airway microbiota in patients with moderate-to-severe COPD. The control arm of&#xD;
      this study will be Oxeze 12 ug BID.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, non-placebo controlled study to evaluate the effects of Symbicort 400&#xD;
      mcg twice daily (BID) and Advair 250 mcg BID over 12 weeks. As the standard of therapy for&#xD;
      COPD is a long-acting muscarinic antagonist (LAMA) treatment, a placebo only group cannot be&#xD;
      ethically justified. The control arm of this study will thus be Oxeze 12 ug BID. The study&#xD;
      will recruit approximately 69 subjects, from St. Paul's Hospital and British Columbia Cancer&#xD;
      Agency, randomized 1:1:1 to the 3 arms in blocks. We anticipate 10 to 15% drop out rate,&#xD;
      which will enable approximately 60 subjects for full analysis.&#xD;
&#xD;
      After the initial enrolment and confirmation of the entry criteria, subjects will perform&#xD;
      spirometry before and following bronchodilation with salbutamol (up to 400 ug). They will&#xD;
      then enter a 4-week run-in period during which all subjects will be withdrawn from inhaled&#xD;
      corticosteroid containing products. They will then be treated with formoterol via Turbuhaler&#xD;
      12 ug BID and short-acting beta-2 agonists as needed (PRN). Subjects may also have LAMA&#xD;
      (either tiotropium 18 ug once daily or glycopyrronium 50 ug once daily) at the discretion of&#xD;
      the attending physician. At the end of the run-in phase, eligibility will be confirmed and&#xD;
      then subjects will undergo pre and post-spirometry, low-dose thoracic computed tomography&#xD;
      (CT) and bronchoscopy. One week post-bronchoscopy, the subjects will be randomized to a&#xD;
      12-week treatment period. Subjects may also have LAMA at the discretion of the attending&#xD;
      physician. At the end of the 12 week treatment period, the subjects will undergo pre- and&#xD;
      post-spirometry and 2nd bronchoscopy. The subjects will be re-evaluated one week following&#xD;
      bronchoscopy and then discharged from the study. All subjects with pulmonary nodule requiring&#xD;
      follow-up will be evaluated by the attending physician and the pulmonary nodule will be&#xD;
      investigated as per guidelines of the Fleischner Society.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total bacterial population in the bronchoalveolar lavage fluid</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bacterial diversity using Shannon Index based on 16S sequencing.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bacterial membership using Beta-diversity</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of bacteria Operational Taxonomic Unit</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total cell count in bronchoalveolar lavage fluid</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total neutrophil count in bronchoalveolar lavage fluid</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total lymphocyte count in bronchoalveolar lavage fluid</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total mono-macrophage count in bronchoalveolar lavage fluid</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in St. George's Respiratory Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in forced expiratory volume in 1 second</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in forced vital capacity</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Fluticasone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advair (fluticasone) 250 mcg to be administered twice daily via Diskus for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbicort (budesonide) 400 mcg to be administered twice daily via Turbuhaler for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxeze (formoterol) 12 microg to be administered twice daily via Turbuhaler for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone group</intervention_name>
    <arm_group_label>Fluticasone group</arm_group_label>
    <other_name>Advair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide group</intervention_name>
    <arm_group_label>Budesonide group</arm_group_label>
    <other_name>Symbicort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol group</intervention_name>
    <arm_group_label>Formoterol group</arm_group_label>
    <other_name>Oxeze</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures.&#xD;
&#xD;
          -  History of moderate to very severe COPD with a post-bronchodilator forced expiratory&#xD;
             volume/forced vital capacity (FEV1/FVC) &lt;0.70 and a post-bronchodilator FEV1&gt;20% and&#xD;
             ≤80% of predicted normal value at screening.&#xD;
&#xD;
          -  Current smoker or ex-smoker with a tobacco history of ≥10 pack-years (1 pack year= 20&#xD;
             cigarettes smoked per day for 1 year).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically important pulmonary disease other than COPD (e.g. active lung infection,&#xD;
             clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis,&#xD;
             hypoventilation syndrome associated with obesity, and primary ciliary dyskinesia) and/&#xD;
             or radiological findings suggestive of a respiratory disease other than COPD that is&#xD;
             contributing to the subject's respiratory symptoms.&#xD;
&#xD;
          -  Any disorder, including, but not limited to, cardiovascular, gastrointestinal,&#xD;
             hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,&#xD;
             haematological, psychiatric, or major physical impairment that is not stable in the&#xD;
             opinion of the Investigator and could:&#xD;
&#xD;
               1. Affect the safety of the subject throughout the study&#xD;
&#xD;
               2. Influence the findings of the study or their interpretation&#xD;
&#xD;
               3. Impede the subject's ability to complete the entire duration of study Subjects&#xD;
                  who have epilepsy must be on a stable dose of medication for 30 days prior to&#xD;
                  Visit 4.&#xD;
&#xD;
          -  Unstable ischemic heart disease, or uncontrolled arrhythmia, cardiomyopathy, heart&#xD;
             failure, and renal failure, or uncontrolled hypertension as defined by the&#xD;
             Investigator, or any other relevant cardiovascular disorder as judged by the&#xD;
             Investigator&#xD;
&#xD;
          -  Treatment with systemic corticosteroids and/or antibiotics, and/or hospitalization for&#xD;
             a COPD exacerbation within 8 weeks prior to enrolment (Visit 1), based on last dose of&#xD;
             steroids or last date of hospitalization whatever occurred later.&#xD;
&#xD;
          -  Acute upper or lower respiratory infection requiring antibiotics or antiviral&#xD;
             medication within 2 weeks prior to enrolment (Visit 1).&#xD;
&#xD;
          -  Pneumonia within 8 weeks prior to enrolment (Visit 1), based on the last day of&#xD;
             antibiotic treatment or hospitalization date, whatever occurred later.&#xD;
&#xD;
          -  Pregnant, breastfeeding, or lactating women.&#xD;
&#xD;
          -  Any clinically significant abnormal findings in physical examination, vital signs,&#xD;
             haematology, clinical chemistry, or urinalysis during screening/run-in period, which,&#xD;
             in the opinion of the Investigator, may put the subject at risk because of his/her&#xD;
             participation in the study, or may influence the results of the study, or the&#xD;
             subject's ability to complete entire duration of the study.&#xD;
&#xD;
          -  Use of immunosuppressive medication, including rectal corticosteroids, high potency&#xD;
             topical corticosteroids and systemic steroids within 28 days prior to randomization.&#xD;
&#xD;
          -  Receipt of blood products within 30 days prior to enrollment (Visit 1).&#xD;
&#xD;
          -  Receipt of any investigational non-biologic product within 30 days or 5 half-lives&#xD;
             prior to Visit 1.&#xD;
&#xD;
          -  History of alcohol or drug abuse within the past year, which may compromise the study&#xD;
             data interpretation as judged by Investigator or Study Physician.&#xD;
&#xD;
          -  Subjects who in the opinion of the investigator or qualified designee have evidence of&#xD;
             active tuberculosis (TB), either treated or untreated.&#xD;
&#xD;
          -  Scheduled in-patient hospitalization or surgical procedure during the course of the&#xD;
             study.&#xD;
&#xD;
          -  Asthma as a primary or main diagnosis according to the Global Initiative for Asthma&#xD;
             (GINA, http://www.ginasthma.org/) guidelines or other accepted guidelines. Subjects&#xD;
             with a past medical history of asthma (e.g. childhood or adolescence) may be included.&#xD;
&#xD;
          -  The male partner of someone who may become pregnant during the course of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Sin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynda Lazosky</last_name>
    <phone>604-682-2344</phone>
    <phone_ext>64884</phone_ext>
    <email>llazosky@providencehealth.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Genevieve Rocheleau</last_name>
    <phone>604-682-2344</phone>
    <phone_ext>64888</phone_ext>
    <email>grocheleau@providencehealth.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynda Lazosky</last_name>
      <phone>604-682-2344</phone>
      <phone_ext>64884</phone_ext>
      <email>llazosky@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Don Sin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Van Eeden Stephanus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leung Janice, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaipanich Tawimas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy English</last_name>
      <email>aenglish@bccrc.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen Lam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eve-lea Beaudoin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Don Sin</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

